FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4212844512> ?p ?o ?g. }

• W4212844512 endingPage "53" @default.
• W4212844512 startingPage "51" @default.
• W4212844512 abstract "Abstract Background Adult data have shown that Infliximab (IFX) impairs the antibody response to a single dose of the mRNA-BNT162b2 SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD). The true impact of IFX on SARS-CoV-2 vaccine efficacy in pediatric IBD (PIBD) patients is unknown. Aims To evaluate the humoral immune response to the BNT162b2 SARS-CoV-2 in PIBD patients treated with anti-tumor necrosis factor (TNF) therapy. Methods PIBD patients treated with anti-TNF therapy either alone or in combination with an immunomodulator, who received at least one dose of the BNT162b2 SARS-CoV-2 vaccine, were prospectively enrolled from 1st June 2021 at BC Children’s Hospital. Serum antibody levels for [spike (S) protein and receptor-binding domain (RBD)] were determined at baseline and 28 days after their first and second vaccine doses. Antibody responses were assessed using multiplex serology IgG assay against four SARS-CoV-2 antigens: S-protein, RBD, N-terminal domain (NTD) and N-protein using the SARS-CoV-2 Panel 2 (Meso Scale Diagnostics). Results Forty-two PIBD patients received a single dose of BNT162b2 (median age 14.5yrs (IQR 14–16); 43% female; 79% crohn’s disease, 21%, ulcerative colitis). Of those on IFX monotherapy (43%), both S-protein and RBD antibody concentrations 28 days post BNT162b2 were comparable to healthy adult controls (n=20, median age: 36yrs (IQR 29–40); 65% female) who had received one dose of BNT162b2 (p = 0.07) [Figure 1]. In PIBD patients on IFX in combination with either azathioprine or methotrexate (57%) both S-protein and RBD antibody concentrations were significantly lower than controls after 1 dose of BNT162b2 (p = 0.0003) [Figure 1]. In the PIBD cohort (n=27) who received 2 doses of BNT162b2 vaccine (median age 14yrs (IQR 14–16);41% female;63% crohn’s disease, 37% ulcerative colitis; median interval between doses 56 days (IQR 22–105)), there was no difference in antibody response after 2 doses compared to healthy adult controls (n=14, median age: 44 years (IQR 36–51); 29% female) whether they were on IFX monotherapy (41%) or in combination with an immunomodulator (59%) [Figure 1]. Conclusions We provide evidence of an attenuated antibody response in PIBD patients on IFX in combination with an immunomodulator after a single dose of BNT162b2. However, our data show a robust antibody response in PIBD patients, despite their infliximab treatment, after two doses of BNT162b2 vaccine. Our results are consistent with adult IBD data and highlight the importance of administering the second vaccine dose to achieve protection in this vulnerable patient population. Long-term follow-up to assess longevity of vaccine protection is warranted. Funding Agencies None" @default.
• W4212844512 created "2022-02-24" @default.
• W4212844512 creator A5001699720 @default.
• W4212844512 creator A5012343529 @default.
• W4212844512 creator A5035862788 @default.
• W4212844512 creator A5073661706 @default.
• W4212844512 creator A5075958430 @default.
• W4212844512 date "2022-02-21" @default.
• W4212844512 modified "2023-10-02" @default.
• W4212844512 title "A45 INFLIXIMAB IN COMBINATION WITH AN IMMUNOMODULATOR IS ASSOCIATED WITH AN ATTENUATED ANTIBODY RESPONSE TO BNT162B2 SARS-COV-2 VACCINE IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS" @default.
• W4212844512 doi "https://doi.org/10.1093/jcag/gwab049.044" @default.
• W4212844512 hasPublicationYear "2022" @default.
• W4212844512 type Work @default.
• W4212844512 citedByCount "0" @default.
• W4212844512 crossrefType "journal-article" @default.
• W4212844512 hasAuthorship W4212844512A5001699720 @default.
• W4212844512 hasAuthorship W4212844512A5012343529 @default.
• W4212844512 hasAuthorship W4212844512A5035862788 @default.
• W4212844512 hasAuthorship W4212844512A5073661706 @default.
• W4212844512 hasAuthorship W4212844512A5075958430 @default.
• W4212844512 hasBestOaLocation W42128445121 @default.
• W4212844512 hasConcept C126322002 @default.
• W4212844512 hasConcept C159654299 @default.
• W4212844512 hasConcept C203014093 @default.
• W4212844512 hasConcept C2777138892 @default.
• W4212844512 hasConcept C2778260677 @default.
• W4212844512 hasConcept C2779134260 @default.
• W4212844512 hasConcept C2780479503 @default.
• W4212844512 hasConcept C2781188995 @default.
• W4212844512 hasConcept C3007834351 @default.
• W4212844512 hasConcept C3008058167 @default.
• W4212844512 hasConcept C3018913218 @default.
• W4212844512 hasConcept C45189115 @default.
• W4212844512 hasConcept C524204448 @default.
• W4212844512 hasConcept C60644358 @default.
• W4212844512 hasConcept C71924100 @default.
• W4212844512 hasConcept C86803240 @default.
• W4212844512 hasConcept C8891405 @default.
• W4212844512 hasConceptScore W4212844512C126322002 @default.
• W4212844512 hasConceptScore W4212844512C159654299 @default.
• W4212844512 hasConceptScore W4212844512C203014093 @default.
• W4212844512 hasConceptScore W4212844512C2777138892 @default.
• W4212844512 hasConceptScore W4212844512C2778260677 @default.
• W4212844512 hasConceptScore W4212844512C2779134260 @default.
• W4212844512 hasConceptScore W4212844512C2780479503 @default.
• W4212844512 hasConceptScore W4212844512C2781188995 @default.
• W4212844512 hasConceptScore W4212844512C3007834351 @default.
• W4212844512 hasConceptScore W4212844512C3008058167 @default.
• W4212844512 hasConceptScore W4212844512C3018913218 @default.
• W4212844512 hasConceptScore W4212844512C45189115 @default.
• W4212844512 hasConceptScore W4212844512C524204448 @default.
• W4212844512 hasConceptScore W4212844512C60644358 @default.
• W4212844512 hasConceptScore W4212844512C71924100 @default.
• W4212844512 hasConceptScore W4212844512C86803240 @default.
• W4212844512 hasConceptScore W4212844512C8891405 @default.
• W4212844512 hasIssue "Supplement_1" @default.
• W4212844512 hasLocation W42128445121 @default.
• W4212844512 hasLocation W42128445122 @default.
• W4212844512 hasOpenAccess W4212844512 @default.
• W4212844512 hasPrimaryLocation W42128445121 @default.
• W4212844512 hasRelatedWork W1572283981 @default.
• W4212844512 hasRelatedWork W191183980 @default.
• W4212844512 hasRelatedWork W2014462309 @default.
• W4212844512 hasRelatedWork W2411114470 @default.
• W4212844512 hasRelatedWork W2576474053 @default.
• W4212844512 hasRelatedWork W2765379856 @default.
• W4212844512 hasRelatedWork W3022383156 @default.
• W4212844512 hasRelatedWork W3114705427 @default.
• W4212844512 hasRelatedWork W4200563690 @default.
• W4212844512 hasRelatedWork W2978685749 @default.
• W4212844512 hasVolume "5" @default.
• W4212844512 isParatext "false" @default.
• W4212844512 isRetracted "false" @default.
• W4212844512 workType "article" @default.